AGÕæÈ˹ٷ½

STOCK TITAN

[6-K] Ascentage Pharma Group International Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
-
-
-
-
-
Positive
  • None.
Negative
  • None.
-
-
-
-
-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2025

 

Commission File Number: 002-023311

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒            Form 40-F ☐

 

 

 

 

 

On July 7, 2025, Ascentage Pharma Group International issued a press release entitled, “Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.

 

1

 

INDEX TO EXHIBITS

 

Exhibit Number    Exhibit Title
99.1   Press Release dated July 7, 2025

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  ASCENTAGE PHARMA GROUP INTERNATIONAL
   
Date: July 8, 2025 /s/ Dajun Yang
  Name: Dajun Yang
  Title: Chief Executive Officer

 

3

 

Ascentage Pharma Group International

NASDAQ:AAPG

AAPG Rankings

AAPG Latest News

AAPG Latest SEC Filings

AAPG Stock Data

3.43B
7.33M
0.16%
Biotechnology
Healthcare
China
Suzhou